Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ARV-393 by Arvinas for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
ARV-393 is under clinical development by Arvinas and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According to...
ARV-393 by Arvinas for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
ARV-393 is under clinical development by Arvinas and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Arvinas's ARV-766?
ARV-766 is a small molecule commercialized by Arvinas, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Risk adjusted net present value: What is the current valuation of Arvinas's Bavdegalutamide?
Bavdegalutamide is a small molecule commercialized by Arvinas, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer (mCRPC)....
Risk adjusted net present value: What is the current valuation of Arvinas's ARV-766?
ARV-766 is a small molecule commercialized by Arvinas, with a leading Phase II program in Metastatic Castration-Resistant Prostate Cancer (mCRPC)....